Skip to main content
Ira Winer, MD, Obstetrics & Gynecology, Detroit, MI

Ira Seth Winer MD PhD

Gynecologic Oncology


Gynecologic Oncology, Karmanos Cancer Institute Associate Professor, Wayne State University

Join to View Full Profile
  • 4100 John RDetroit, MI 48201

  • Phone+1 313-576-9435

  • Fax+1 313-576-8988

Dr. Winer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Meet Dr. Ira S. Winer - Gynecologic Oncology

    Ira S. Winer, M.D., Ph.D., member of the Gynecologic Oncology Multidisciplinary Team at the Barbara Ann Karmanos Cancer Institute.

Education & Training

  • Detroit Medical Center/Wayne State University
    Detroit Medical Center/Wayne State UniversityFellowship, Gynecologic Oncology, 2011 - 2015
  • University of Michigan
    University of MichiganResidency, Obstetrics and Gynecology, 2007 - 2011
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 2007
  • University of Michigan
    University of MichiganPhD, The Cellular and Molecular Biology Program, 2001 - 2005
  • Boston University
    Boston UniversityBA, Biochemistry, Molecular Biology, Summa Cum Laude, 1999

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2011 - 2027
  • OH State Medical License
    OH State Medical License 2010 - 2011
  • Obstetrics & Gynecology
    American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • Gynecologic Oncology
    American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • CCITLA award NCI, 2019-2020
  • 1st Prize in Fellow Research Section ACOG Research, 2012
  • Distinction in Research University of Michigan Medical School, 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Merkel cell carcinoma in a patient with noninvasive vulvar Paget's disease  
    Winer IS, Lonardo F, Johnson SC, Deppe G., Am J Obstet Gynecol, 3/30/2013
  • Chemotherapy of vulvar cancer: A Review  
    Deppe G, Mert I, Belotte J, WinerIS, Wien KlinWochenschr, 3/1/2013
  • Clinical and Pathologic Characteristics of Serous Carcinoma Confined to the Endometrium: A Multi-institutional Study  
    Seeman A, Mert I, Munkarah A, Bandyopadhyay S, Winer I, et al., Int J GynecolPathol, 3/1/2013
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • The significance of squamous vs. adenocarcinoma subtypes in early stage cervical carcinoma
    Winer I, Alvarado-Cabrero I, Seward S, Valencia-Cedillo R, Munkarah A, Ali-Fehmi R., American Association of Cancer Research Annual Meeting, 4/1/2013
  • A multi-institutional clinic-pathologic study of USC without myometrial invasion
    Winer I, Semaan A,Mert I, Hayek K, Bandyopadhyay S, Nucci MR, Van de Vijver KK, Hussein Y, Alosh B, Oliva E, Ali-Fehmi R, International Gynecologic Cancer Society (IGCS),, 10/1/2012
  • Activation of the unfolded protein response (UPR) by disulfiram in ovarian cancer cells: A novel therapeutic mechanism to overcome chemoresistance
    Winer et al., International Journal of Gynecological Cancer, 10/1/2012
  • Join now to see all

Press Mentions

  • Big Phase 3 Wins in Lung Cancer and More: Antibody-Drug Conjugate News Rapid Roundup
    Big Phase 3 Wins in Lung Cancer and More: Antibody-Drug Conjugate News Rapid RoundupJune 26th, 2025
  • Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
    Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 TrialJune 2nd, 2025
  • Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
    Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 TrialJune 2nd, 2025
  • Join now to see all

Professional Memberships

Other Languages

  • Hebrew

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: